Ewing Sarcoma
Primary objectives:
Standard Risk R1: in a randomised trial, to examine whether add-on treatment with zoledronic
acid in addition to induction and maintenance chemotherapy improves event-free survival in
patients with localised Ewing sarcoma and good histological response or with initial tumour
volume <200 mL compared to no add-on treatment.
*High Risk R2: in a randomised trial, to examine whether high-dose chemotherapy using
busulfan-melphalan with autologous stem cell reinfusion, compared with standard chemotherapy,
improves event-free survival in patients with localised Ewing sarcoma and poor histological
response or tumour volume ≥200 mL (R2loc). In patients with pulmonary metastases high dose
busulfan-melphalan chemotherapy with autologous stem cell reinfusion is randomised versus
standard chemotherapy plus whole lung irradiation (R2pulm).
Very High Risk R3: in a randomised trial, to examine whether the addition of high dose
chemotherapy using treosulfan-melphalan followed by autologous stem cell reinfusion to eight
cycles of standard adjuvant chemotherapy, compared to eight cycles of standard adjuvant
chemotherapy alone, improves event-free survival in patients with primary disseminated
disease.
*R2 accrual discontinued on December 1st 2015.